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To assess whether pregnancy might influence the function-
ality and expression of human myometrial 2- and 3-adreno-
ceptors (2- and 3-AR), we performed functional, binding,
Western blot, and molecular biology experiments in human
nonpregnant and near-term pregnant myometrium. Inhibi-
tion of spontaneous contractions induced by a 3-AR agonist,
SR 59119A, was significantly greater in pregnant, compared
with nonpregnant, myometrial strips (Emax 61 5% vs. 44
5% for pregnant andnonpregnantmyometrium, respectively),
whereas salbutamol, a 2-AR agonist, was significantly less
efficient in pregnant, compared with nonpregnant, myome-
trium (Emax 29 4 vs. 54 8%). Although two populations of
binding sites corresponding to 2- and 3-AR were identified
in both nonpregnant and pregnant myometrium, we found a
clear predominance of the 3-AR subtype. Moreover, 3-AR
binding sites were up-regulated 2-fold in myometrium at the
end of pregnancy. Both 2- and 3-AR mRNA were expressed
in human nonpregnant and pregnant myometrium. Contrary
to 2-AR, the expression of the 3-AR transcripts and immu-
noreactive proteins was increased in pregnant, compared
with nonpregnant, myometrium. Such compelling data sug-
gest a predominant role for 3-AR in the regulation of human
myometrium contractility, especially at the end of pregnancy,
which might have important consequences for the clinical
management of preterm labor. (J Clin Endocrinol Metab 90:
1644–1650, 2005)
THE INCIDENCE OF premature birth has risen overthe past 15 yr, mainly because of medically induced
births, yet spontaneous preterm delivery still remains sta-
ble and relatively high in developed countries despite
preventative measures (1, 2). Approximately 6–12% of all
pregnancies end up prematurely inWestern countries, and
deaths of premature babies represent approximately 85%
of all perinatal mortality. Several stimulatory and inhib-
itory pathways regulate the balance of uterine quiescence
and contractile activity during pregnancy. The mecha-
nisms that govern the switch between these opposing
functional states are still poorly understood. Worldwide,
2-adrenoceptor (AR) agonists are the most commonly
used tocolytic agents. However, besides their maternal
and fetal side effects, their efficacy remains controversial
(3, 4). 2-ARs may vary according to hormonal status in
human (5) or rat (6). The different proportion of each -AR
in pregnant and nonpregnant myometrium in goat and
cow was suggested over 20 yr ago by Larsen (7). We
previously demonstrated that 2-ARs were predominant
(65%) over 1-AR in the human pregnant myometrium
and that the number of -ARs was diminished at the end
of pregnancy (8). An additional -AR subtype, the 3-AR,
has since been characterized (9), and its functionality has
been recently shown in the human near-termmyometrium
(10). Because adrenergic responsiveness is dependent on
hormonal regulation (11, 12), we studied the status of the
3-AR in comparison with the 2-AR in the myometrium
of near-term and nonpregnant women. More specifically,
we investigated the functional contractile inhibition of
specific 2- and 3-AR agonists, salbutamol and SR
59119A, respectively, concomitantly with the binding
properties and the expression of the transcripts and the
immunoreactive proteins of these receptors.
Materials and Methods
Biological samples
Myometrial biopsies were obtained from nonpregnant cycling
women undergoing hysterectomy for benign gynecological indications
or from pregnant women delivered by elective cesarean section before
the onset of labor (38–40 wk of pregnancy) because of a diagnosed
cephalopelvic disproportion in an otherwise uncomplicated normal
pregnancy. Myometrial strips were excised from an immediately sub-
serosal site in which the majority of the fibers are in a longitudinal
orientation at an antiplacental site, as previously described (13). This
study was approved by the Comite´ Consultatif de Protection des Per-
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sonnes pour la Recherche Biome´dicale (Paris-Cochin, France), and writ-
ten informed consent was obtained from all donors.
Functional contractile study
Segments of myometrium (8–12  2–3 mm) were suspended iso-
metrically under a resting tension of 2 g in a 10-ml organ bath containing
Krebs solution (composition, millimoles: NaCl, 118; KCl, 5.4; CaCl2, 2.5;
KH2PO4, 0.6; MgSO4, 1.2; NaHCO3, 25; glucose, 11.7; ascorbic acid, 0.1)
maintained at 37 C and continuously exposed to a mixture of 95%
oxygen-5% carbon dioxide (pH 7.4). The 2-g initial tension was chosen
according to previous reports including our own experiments (10, 14).
One end of each strip was connected to a force-displacement transducer,
and tension changes were measured using Pioden strain gauges (UF1)
that were amplified (EMKA, Paris, France) and recorded on a pen-
writing oscillograph (Linseis, L65514, Munich, Germany). After 1 h,
during which the myometrial strips were washed every 15 min and the
resting tension readjusted to 2 g, the strips were then allowed to equil-
ibrate for an additional hour until they showed regular spontaneous
rhythmic contractile activity. Once contractions became regular in both
amplitude and frequency, cumulative concentration-response curves
(CRCs) (from 0.01 m to 30 m) were determined to characterize the
effects of exposure to either SR 59119A (3-AR agonist, Sanofi-Aventis,
Milan, Italy) or salbutamol (2-AR agonist, Sigma, St. Quentin Fallavier,
France). The exposure time for each additional concentration was
around 20–40 min, time necessary to reach a plateau of contractions.
Because 3–4 h were necessary for the construction of a cumulative CRC,
only one complete curve was obtained for each strip. Because we pre-
viously described that there was no time-related loss of contractions
during our experiments (10, 13), we did not use time-matched control
in this study. For salbutamol, because saturation of CRCs was reached,
the maximal effect (Emax) was determined as a percentage of inhibition
of initial amplitude of spontaneous contractions.
Potency was expressed as pIC50, which is the log IC50, where IC50
is the concentration of agonist producing half of its maximal response.
Because saturation of CRC was not reached for SR 59119A, Emax indi-
cates themaximal response obtained at themaximal concentration tested
(30 m), and potency was not calculated. Data were analyzed by non-
linear regression sigmoidal dose-response curve using the Prism 4.01
software (GraphPad Software, San Diego, CA). The equation curve is
Y  Ymin  (Ymax  Ymin)/[1  10ˆ (log IC50X)] where X is the
logarithm of concentration, Y is the response, Ymin is the minimal in-
hibitory effect, and Ymax, the maximal inhibitory effect.
Binding studies
Crudemembranes were prepared from different biopsy specimens of
near-term pregnant or nonpregnant myometrial tissues as reported pre-
viously (8, 15).Membraneswere diluted at a protein concentration of 1–3
mgml1, in a cold 50mm Tris-HCl (pH 7.4) buffer. Protein concentration
was determined by the method of Bradford (16) using BSA as standard.
Binding studies were performed at 30 C for 60 min in a 0.25-ml crude
membrane preparation (12 g protein per sample) that contained 50mm
Tris-HCl (pH 7.4), 154 mm NaCl, 0.1% BSA, and ()-[125I]iodocyan-
opindolol (ICYP) from 2 to 1000 pm (saturation analysis). The ICYP
(specific activity 2200 Ci/mmol) was obtained from PerkinElmer Life
Sciences (Boston, MA). Reactions were terminated by dilution with 5 ml
of ice-cold 50 mm Tris-HCl (pH 7.4), 0.01% Triton X-100, and filtration
over glass-fiber filters (Whatman GF/C, Maidston, UK) presoaked in
0.1% BSA in 50 mm Tris-HCl (pH 7.4). The filters were washed with an
additional 15 ml of 50 mm Tris-HCl (pH 7.4) and 0.01% X-100 Triton,
dried, and counted on a Packard -counter with 85% efficiency.
In previous studies examining2-AR (8), specific bindingwasdefined
as the difference between the amount of ICYPbound in the absence (total
binding) and presence (nonspecific binding) of 500 m unlabeled ()-
isoproterenol (Sigma). For 3-AR binding studies, nonspecific binding
was defined by the amount of ICYP bound in the presence of unlabeled
()-alprenolol (500 m, Sigma). Competition experiments were carried
out at a fixed concentration of ICYP (400 pm) with increasing concen-
trations of competing agents and in the presence of 0.1 m ()-pro-
pranolol to block 1- and 2-AR (17). At ligand concentrations near the
ICYP dissociation constant (KD), nonspecific binding was less than 15
and 30% of total binding for 2- and 3-AR, respectively. The inhibition
constants values (Ki) were calculated by the equation of Cheng and
Prusoff (18): Ki  IC50/(1  [L]/KD), where IC50 is the concentration of
competing agent producing 50% of a maximal response, [L] is the con-
centration of ICYP used in the assay, and the appropriate KD value is the
dissociation constant of ICYP as determined by nonlinear regression.
Radioligand binding data were analyzed by nonlinear regression using
the GraphPad Prism 4.01 software. Results are expressed as sem.
RT and PCR analysis
As described previously (15, 19), extraction of total RNA from myo-
metrial tissues using the Trizol reagent method, reverse transcription
using Muloney murine leukemia virus reverse transcriptase, and PCR
using Taq DNA polymerase were performed under the conditions rec-
ommended by the manufacturer (Life Technologies, Cergy Pontoise,
France). The primers were designed according to Roberts et al. (20).
The amplification profile for 2- and 3-AR consisted in denaturation at
94 C for 1 min, annealing at 64 C for 1 min, extension at 72 C for 1 min
with a final extension at 72 C for 10 min. An aliquot from the PCR
mixture was resolved by electrophoresis on a 2% agarose gel (Life
Technologies) and visualized by ethidium bromide staining under UV
light. To check the size of PCR products, a DNA molecular mass stan-
dard ladder (123-bp DNA ladder, Life Technologies) was concomitantly
subjected to electrophoresis. An additional control of validity was car-
ried out using Southern blot analysis of the PCR products with specific
internal oligonucleotides (data not shown). Amplification of an endog-
enous marker, the human 2-microglobulin cDNA (21), was performed
as internal control. Absence of DNA contamination was confirmed by
conducting PCR control reactions containing mRNA without reverse
transcriptase. The intensities of the bands on Polaroid pictures of the
ethidium bromide staining gel were analyzed densitometrically using
the NIH Image 1.62 program (National Institutes of Health, Bethesda,
MD). Results are expressed as relative levels [arbitrary densitometric
units (ADUs)] of specificmRNAnormalized to 2-microglobulinmRNA
in each sample.
Western blotting analysis
Snap-frozen myometrial tissues obtained from nonpregnant and
near-term pregnant women were homogenized with Ultra-Turrax in
homogenization buffer [10 mm Tris-HCl (pH 7.4), 1 mm EDTA, 40
mgml1 leupeptine, 2 mm Pefabloc]. After an initial centrifugation at
500 g for 15 min at 4 C, the supernatant was removed and centrifuged
at 48,000  g for 20 min at 4 C. The resulting pellet was suspended in
solubilization buffer (300 mm NaCl, 50 mm Na2HPO4, 1% Triton X-100)
overnight at 4 C. A further centrifugation was performed at 48,000  g
for 20 min at 4 C. Total protein content was determined by the Bradford
method with BSA as standard. Samples (40 g protein by lane) were
dissolved (vol/vol) in 2 Laemmli buffer (22) and boiled for 5 min
before electrophoresis on a 10% SDS-PAGE. Proteins were transferred
to a nitrocellulose membrane (Hybond-P, Amersham Biosciences,
Freiburg, Germany). To block nonspecific antibody binding, blots were
incubated for 1 h in 10% nonfat dried milk powder in Tris-buffered
saline/Tween 20 (TBST) [10 mm Tris, 150 mmNaCl, and 0.1% Tween 20
(pH 7.8)] at room temperature. Blocked membranes were washed three
times with TBST. The blots were then incubated overnight at 4 C with
a 1:500 dilution of primary 2-AR polyclonal antibody (H-20, sc-569,
Santa Cruz Biotechnology, Santa Cruz, CA) or a 1:500 dilution of pri-
mary 3-AR polyclonal antibody (AB5122, Chemicon International, Te-
mecula, CA) in 1% nonfat dried milk powder in TBST. After three
washes with TBST, the blots were incubated for 45minwith horseradish
peroxidase-conjugated antirabbit IgG whole antibody (NA 934, Amer-
sham) at a dilution of 1:5000 at room temperature andwashed five times
with TBST. Immunoreactive proteins were detected by chemilumines-
cence (ECLdetection reagents, RPN2105, AmershamPharmacia Biotech,
Little Chalfont, UK). The intensities of the bands were analyzed den-
sitometrically using the NIH Image 1.62 program. Results are expressed
as the mean  sem in ADUs. The specificity of each immunoreactive
band was assessed by specific blocking in the presence of the respective
antigenic peptide againstwhich the antibodies have been raised (sc-569P
from Santa Cruz Biotechnology for 2-AR and AG388 from Chemicon
International for 3-AR).
For preadsorption, a mixture of each primary antibody with its re-
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spective antigen (1:5) was incubated under mild agitation in a small
volume of PBS buffer for 2 h at room temperature (for 2-AR) or 24 h
at 4 C (for 3-AR). In addition, homogenate of Chinese hamster ovary
(CHO) cells transfected with the human 3-AR (graciously provided by
Dr. P. Marini, Sanofi-Aventis Research Center, Milan, Italy) was used as
positive control.
Drug and solution
SR 59119A (N-[(7-methoxy-1,2,3,4-tetrahydronaphtalen-(2R)-2-yl)-
methyl]-(2R)-2-hydroxy-2-(3-chlorophenyl)ethanamine hydrochloride)
was a gift from Sanofi-Aventis, Sanofi-Aventis Research Center. SR
59119A was dissolved in a mixture of absolute ethanol 30%, dimethyl-
sulfoxide 2%, and distilled water for the 30-m solution and thereafter
diluted in distilled water. Salbutamol sulfate was dissolved in distilled
water. In the functional studies, drug concentrations were given as final
bath concentrations.
Statistical analysis
In the functional experiments, differences among groups were de-
termined by ANOVA and expressed with a t test using the Bonferroni
correction. Differences in potencies and maximal effects, as well as
differences among groups in binding experiments, were determined by
Student’s t test for unpaired data or ANOVA as appropriated. All
differences were considered significant when P  0.05.
Results
Functional contractile study
Application tomuscle strips of SR 59119A ranging from0.1
to 30 m caused a concentration-dependent inhibition of the
spontaneous contractile activity of myometrium obtained
from nonpregnant or near-term women (Fig. 1). A compar-
ison of the CRC for both 2- and 3-AR agonists in pregnant
and nonpregnant myometrium is shown in Fig. 2, A and B.
Application to muscle strips of salbutamol or SR 59119A,
ranging from 0.01 to 30 m, caused a concentration-depen-
dent inhibition of the spontaneous contractile activity of
myometrial strips obtained from nonpregnant or near-term
pregnant women. In the near-termmyometrium, salbutamol
effect was weaker and the CRCwas downward shifted, com-
pared with that obtained in the nonpregnant myometrium
(Fig. 2A, ANOVA, P  0.001). The Emax value of salbutamol
was significantly (P 0.05) lower in the pregnant than in the
nonpregnant tissue (Emax 29 4 and 54 8% for pregnant
and nonpregnant myometrium, respectively), whereas no
significant differencewas observed between the pIC50 values
(Table 1). SR 59119A was responsible for a strong inhibition
of spontaneous contractions in both the pregnant and non-
pregnant myometrium (Fig. 2B). In contrast to salbutamol,
the CRC of SR 59119A obtained in the near-term myome-
trium was shifted to the left, compared with that obtained in
the nonpregnant myometrium (Fig. 2B, ANOVA, P  0.01).
This was associated with an increase, although not statisti-
cally significant, in Emax values (61  5 vs. 44  5% for
pregnant and nonpregnant myometrium, respectively)
(Table 1). In pregnant myometrium, the CRC of salbutamol
was shifted to the right, compared with that of SR 59119A
(ANOVA, P  0.01), and the effect obtained at the maximal
dose tested (30m) was lower for salbutamol than SR 59119A
(29  4 vs. 61  5% for salbutamol and SR 59119A, respec-
tively, P  0.001) (Table 1).
Characterization of 2- and 3-AR binding sites
ICYP bound to membrane preparations of nonpregnant
and pregnant myometrium in a concentration-dependent
manner. Scatchard representation of saturation curve is
shown in Fig. 3A. In pregnant myometrium, nonlinear anal-
ysis of the saturation curve demonstrated the appearance of
a two-site plot, indicating both a low-affinity site [KD 771
109 pm; maximal binding capacity (Bmax)  92.9  13.1
fmolmg1 protein] and a high-affinity site (KD 39 4 pm;
Bmax  4.9  0.6 fmolmg
1 of protein) (Table 2). Consistent
FIG. 1. Representative recording of the effect of SR 59119A on spontaneous contractions of human nonpregnant (upper trace) and near-term
(lower trace) myometrial strips.
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with our previous results and those from other groupswork-
ing onhumanpregnantmyometrium (8, 23), the high-affinity
binding site found here resembled that of a 2-AR profile.
The identity of the low-affinity binding site was confirmed
by competition binding experimentswith the selective3-AR
agonist. SR 59119A competed at the propranolol-resistant
ICYP binding site (Fig. 3B) with a Ki value of 276  76 nm.
Competition binding data were similar (Ki  154  82 nm)
in nonpregnant myometrium (data not shown). It should be
noted that the slope value for these curves was low (Hill
coefficient nH 0.71 and 0.65 in nonpregnant and pregnant
myometrium, respectively), indicating that two sites may be
present but cannot be significantly differentiated by com-
puter analysis. Nonlinear analysis of saturation curves re-
vealed that the KD values of 3-AR in the nonpregnant and
pregnant myometrium were significantly (P  0.005) differ-
ent (Fig. 3A and Table 2). In addition, the Bmax of 3-AR was
significantly (P 0.01) greater in pregnant than nonpregnant
myometrium (Fig. 3A and Table 2). For 2-AR, the KD values
between nonpregnant and pregnant myometrium were not
significantly different, just as were the Bmax values (Table 2).
Expression of 2- and 3-AR transcripts
As illustrated in Fig. 4A, electrophoresis on agarose gel
stainedwith ethidiumbromide revealed PCRproducts of the
correct predicted sizes, 417 bp for 2-AR and 368 bp for
3-AR, in both pregnant and nonpregnant myometrial sam-
ples. We confirmed successful normalization of RNA
amounts by obtaining equivalent intensity for the 2-micro-
globulin band in pregnant and nonpregnant tissues. Densi-
tometric analysis of the gels indicated a slight decrease in the
signal for 2-ARmRNA (27.4%) in near-termmyometrium
comparatively with nonpregnant tissue, whereas the signal
for 3-AR mRNA was increased in pregnant myometrium
(66.3%) (Fig. 4B).
Expression of 2- and 3-AR immunoreactive proteins
Western blotting of plasma membranes prepared from
nonpregnant and pregnant myometrium revealed a 67-kDa
band corresponding to 2-AR (24) (Fig. 5A). For 3-AR, the
Western blotting revealed a main 68-kDa band (Fig. 5A),
which disappears in the presence of the corresponding block-
ing peptide (data not shown). As positive control, a 68-kDa
band was observed with a homogenate of CHO cells trans-
fected with the human 3-AR that was also specifically
blocked by the antigenic peptide (data not shown). Densi-
tometric immunoblot analysis indicated no change in the
intensity of the signal for the 2-AR in the myometrium of
near-term, compared with nonpregnant, women. At the op-
posite, an increase (40%) in the intensity of the signal for
the 3-AR protein was observed in pregnant, compared with
nonpregnant, myometrium (Fig. 5B).
Discussion
A few years ago, we first described the presence of a
functional 3-AR positively coupled to cAMP production in
human near-term myometrium (10). We recently demon-
strated that contrary to 2-ARs, 3-ARs are less prone to
sustained agonist-induced desensitization in near-termmyo-
metrium (15). The present study strengthens these previous
reports by providing the first evidence not only that 3-ARs
are present but also that they are the predominant subtype,
compared with the 2-ARs, both in human nonpregnant and
pregnant myometrium (10- and 20-fold more numerous, re-
spectively). Furthermore, our results indicate that human
3-ARs are up-regulated in pregnancy.
These new findings appear to contradict the conventional
belief that in human (8, 23) and other species (25, 26), 2- and
1-ARs account, respectively, for approximately 65 and 35% of
the entire myometrial -AR population. 3-ARs have not pre-
viously been detected, probably due to their low affinity for the
ICYP ligand commonly used for -AR binding studies. Com-
plementary approaches combining functional, binding, West-
ern blotting, and molecular biology experiments were carried
out to fully characterize the changes thatmight occur regarding
myometrial-ARstatusat theendofpregnancy.Our functional
TABLE 1. Maximal effect (Emax and Emax) and potency (pIC50)
values for salbutamol and SR 59119A on spontaneous contractile
activity of myometrium from nonpregnant and near-term pregnant
women
Salbutamol
(2-AR agonist)
SR 59119A
(3-AR agonist)
n Emax pIC50 n Emax pIC50
Nonpregnant 11 54  8% 6.74  0.15 12 44  5% ND
Pregnant 31 29  4%a 6.11  0.11 24 61  5% ND
n, Number of experiments; ND, not determined. Each experiment
was conducted on tissue from a different patient.
a P  0.05 vs. nonpregnant.
FIG. 2. Effect of salbutamol (2-AR ag-
onist, A) or SR 59119A (3-AR agonist,
B) on spontaneous contractions of myo-
metrium from nonpregnant (white cir-
cles) or pregnant (black circles) women.
Results are expressed as mean  SEM
(n  11–31).
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experiments demonstrated that the selective 3-AR agonist, SR
59119A, was a more efficient inhibitor of spontaneous contrac-
tions in pregnant than nonpregnant myometrium. The 2-AR
agonist salbutamol, in contrast, displayed a weaker inhibition
of spontaneous contractions in the near-term, compared with
the nonpregnant, myometrium. Few studies have been per-
formed to compare nonpregnant and pregnant myometrial tis-
sues. In 1979, Larsen (7) reported that isoproterenol, a nonse-
lective -AR agonist, and salbutamol and ritodrine, both
selective 2-AR agonists, caused a concentration-dependent re-
laxation of pregnant goat and cowmyometrium, whereas only
isoproterenol was able to reduce the amplitude of spontaneous
contractions of nonpregnant myometrium from the same
animals.
Binding competition studies, transcripts, and protein anal-
ysis were performed concurrently to determine whether any
changes in the mRNA and protein expression and the num-
ber of 2- and 3-AR binding sites might explain the ob-
served change in the contractile response of nonpregnant
and pregnant myometrium to 2- and 3-AR agonists. Ac-
cording to the work of Gsell et al. (27), we found no modi-
fication in the number of2-ARbinding sites in nonpregnant,
compared with pregnant, human myometrium. We con-
firmed these results by Western blotting because, in agree-
ment with Chanrachakul et al. (24), we did not find any
convincing difference in the level of expression of 2-AR
immunoreactive protein between human nonpregnant and
near-term myometrium. Analysis of the level of transcripts
revealed a slight decrease in 2-ARmRNA in pregnant, com-
pared with nonpregnant, women. This discrepancy between
changes in mRNA expression and the number of binding
FIG. 3. A, Representative Scatchard saturation plot of total binding
of ICYP to human nonpregnant and pregnant myometrial mem-
branes. Although linear Scatchard plots are represented in this fig-
ure, a nonlinear regressionmethod was used to determine the KD and
Bmax values. B, Competition between ICYP and SR 59119A (3-AR
agonist) for binding sites in membrane preparations of myometrium
from pregnant women. Results are expressed as mean  SEM from
eight different pregnant women.
FIG. 4. A, Representative RT-PCR analysis of the mRNA steady-
state levels for 2- and 3-AR in human nonpregnant (NP) and preg-
nant (P) myometrium. The 123-bp DNA ladder (123) was used to
estimate the size of the PCR products, and 2-microglobulin expres-
sion was used as a standard reference. These experiments were per-
formed on myometrium from six pregnant and six nonpregnant
women. B, Densitometric analysis of the relative expression of 2- and
3-AR transcripts in myometrium of nonpregnant (NP) and pregnant
(P) women. A.D.U. represents the ratio between the intensity of the
PCR fragments for 2- or 3-AR and the intensity of the signal for
the internal standard 2-microglobulin. Each bar represents the
mean  SEM from six different women.
TABLE 2. Affinity (KD) and number of 2- and 3-AR binding
sites (Bmax) determined after saturation binding experiments in
human nonpregnant and pregnant myometrium
2-AR 3-AR
Nonpregnant Near-term Nonpregnant Near-term
n 3 4 6 8
KD (pM) 78  28 39  4 218  66 771  109
a
Bmax (fmolmg
1
of protein)
4.4  1.2 4.9  0.6 40.0  4.9 92.9  13.1b
n, Number of patients.
a P  0.005 vs. nonpregnant myometrium.
b P  0.01 vs. nonpregnant myometrium.
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sites has already been described (28), andmight be explained
by an increased stability of mRNA, an enhanced translation
rate, or a low receptor turnover (29, 30). The difference in the
relaxant effect of salbutamol observed between nonpregnant
and pregnant myometrium cannot be completely cleared up
by our molecular and biochemical results, and we speculate
that changes in coupling between receptor and adenylyl
cyclase in both tissues are likely to explain these data.
Contrary towhatwasobserved for2-ARs, the increase in the
level of expression of3-AR transcripts in near-term, compared
with nonpregnant, myometrium was associated with an in-
crease of the signal for the corresponding immunoreactive pro-
tein and accompanied by an increase in the number of 3-AR
binding sites. Based on the differences in affinity for ICYP, we
established that human myometrial 3-ARs have a lower af-
finity than 2-ARs. These results are in accordance with the
atypically low affinity and potency of 3-ARs for conventional
-ARantagonists (31). Such lowaffinity of3-ARs for ICYPwas
also found in another smooth muscle, the internal anal sphinc-
ter (32), a tissue in which the 3-AR is predominant over the
1/2-AR subtypes. The SR 59119A effect appears to be selec-
tive of a 3-AR stimulation and not linked to a nonselective
binding on 2-ARs. Indeed, we have previously shown that SR
59119A-induced inhibition of human colon (33) or near-term
myometrium (10) spontaneous contractions was unaffected by
the blockade of1- and2-ARs bypropranolol (0.1m) butwas
significantly reduced by the selective 3-AR antagonist SR
59230A (1 m). Furthermore, functional studies on human iso-
lated bronchi, a tissue that expresses predominantly the 2-AR
subtype, have shown that SR 59119Awas devoid of any 2-AR
agonist (33) or antagonist (34) properties.
Our study confirms, as previously shown in either human
(8) or rat (35) that pregnancy might influence -AR expres-
sion. The influence of sexual hormones on the expression of
myometrial 2-AR is well documented. Progesterone may
increase the density of 2-AR in late-pregnant rats (12) by
controlling the transcription rate of the gene (11). In guinea
pig, estradiol treatment resulted in a marked up-regulation
of 2-AR density, whereas progesterone influenced 2-AR to
a lesser degree (36). By contrast, little is known about mod-
ulation of 3-ARs by steroid hormones. Pregnancy in the
human is associated with a progressive rise in the myome-
trial 17-estradiol to progesterone ratio (37), and it is of
interest to note that an increase in the myometrial response
to a 3-AR agonist was observed near term when this hor-
monal ratio is the most elevated, compared with the non-
pregnant myometrium. Recent results on brown adipocytes
demonstrated that estradiol and progesterone are able to
modify 3-AR affinity and density (38). These data allow us
to hypothesize that hormonal changes observedduring preg-
nancy are likely to explain the modulation of 2- and 3-AR
expression, functionality, and affinity observed in pregnant,
compared with nonpregnant, myometrium. However, such
a hypothesis remains to be tested with further experiments.
One of the major limitations for 2-AR agonists’ use in
clinical practice is their maternal and fetal cardiovascular
side effects. The presence and function of 3-AR in the car-
diovascular system are still a matter of debate (39, 40). How-
ever, clinical trials regarding the effect of 3-AR agonists on
human metabolism did not reveal any change in heart rate,
blood pressure, plasma glucose, insulin, or potassium levels
(41–43). Another limiting factor for the use of selective2-AR
agonists as tocolytic drugs is that their effect, if any, appears
to be of relatively short duration (44). This loss of efficacy is
due in part to desensitization of their receptors. A distin-
guishing feature of the 3-AR, compared with 2-AR, sub-
type is its relative lack of desensitization either in vitro or in
vivo after activation with agonists (15, 45).
In conclusion, the present study provides compelling ev-
idence for the predominance of the 3-AR subtype in the
human myometrium and its up-regulation in pregnancy. In
light of these findings and our recent data on their resistance
FIG. 5. A, Representative Western blot
analysis of 2- and 3-AR expression in
plasma membranes from myometrium
of nonpregnant and pregnant women.
Expected sizes are 67kDa for2-ARand
68 kDa for 3-AR. These experiments
were performed on myometrium from
five nonpregnant and five pregnant
women. Homogenate of CHO cells
transfected with the human 3-AR (3-
CHO) was used as positive control. B,
Analysis of the expression of 2- and
3-AR immunoreactive proteins inmyo-
metrium of nonpregnant and pregnant
women. A.D.U. represents the intensity
of the bands evaluated by densitometry.
Each bar represents the mean  SEM
from five different nonpregnant and
five different pregnant women.
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to desensitization (15), we suggest that 3-AR agonists may
have considerable future pharmaceutical implications in the
clinical management of preterm labor.
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